• Explore /
  • Poster
  • / Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

Abstract Video & Slides Poster

Authors

null

Julien Mazieres

Thoracic Oncology Department, CHU Toulouse–Hôpital Larrey, Toulouse, France

Julien Mazieres , Claire Lafitte , Charles Ricordel , Laurent Greillier , Jean-Louis Pujol , Gerard Zalcman , Charlotte Domblides , Jeannick Madelaine , Jaafar Bennouna , Celine Mascaux , Denis Moro-Sibilot , François Pinquié , Alexis Cortot , Josiane Otto , Jacques Cadranel , Alexandra Langlais , Franck Morin , Virginie Westeel , Benjamin Besse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03845270

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9015)

DOI

10.1200/JCO.2021.39.15_suppl.9015

Abstract #

9015

Abstract Disclosures

Similar Posters

First Author: Nicholas Patrick McAndrew

First Author: Sayeh Moazami Lavasani

First Author: Akihiko Shimomura

First Author: Jennifer Gao